Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin Cardiovascular Effects on Patients at End-stage Renal Disease

NCT05685394 is registered in ClinicalTrials.gov with University of Campinas, Brazil as lead sponsor.

NCT NCT05685394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05685394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin Cardiovascular Effects on Patients at End-stage Renal Disease
Lead sponsor
University of Campinas, Brazil
Phase
Phase 4
Overall status
Unknown status
Start date
January 24, 2023
Completion date
December 1, 2024
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end-stage kidney disease